A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

NCT07490262 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

680

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Capecitabine
DRUG: Oxaliplatin
BIOLOGICAL: IBI310
BIOLOGICAL: Sintilimab

Sponsor

Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.